

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA of golimumab for the treatment of psoriatic arthritis

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

There were no equalities issues related to groups currently protected by the equalities legislation were raised during consultation on the draft scope.
---

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No equalities issues related to groups currently protected by the equalities legislation were raised in the submissions, expert statements or academic report.
--

- |  |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No other issues were identified.
----------------------------------

- |  |
|--|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other |
|--|

groups? If so, what are the barriers to access for the specific group?

As the preliminary recommendations do not recommend golimumab as a treatment option within the NHS, there are not considered to be any barriers to access for any one specific group.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

No barriers to access were identified.

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

No equalities issues were identified.

**Approved by Associate Director (name):** Frances Sutcliffe

**Date:** 3 March 2011

### **Final appraisal determination**

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No issues raised related to groups currently protected by the equalities

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

Yes. The Committee discussed the discontinuation of treatment with etanercept, infliximab and adalimumab in TA 199. The Committee considered that the recommendation to discontinue treatment based on an inadequate Psoriatic Arthritis Response Criteria (PsARC) response at 12 weeks included in TA 199 was also appropriate for golimumab. The Committee was aware that there may be some circumstances that could affect a person's responses to components of the response criteria of the PsARC (such as any physical, sensory or learning disabilities, or communication difficulties), and therefore could affect continuation of treatment with golimumab.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Yes. The Committee concluded that in such cases as described above, healthcare professionals should make any adjustments they consider appropriate. As a result, the following has been included in the recommendations (section 1.2):

When using the PsARC (as set out in NICE technology appraisal guidance 199), healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's responses to components of the PsARC and make any adjustments they consider appropriate.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Committee's considerations of equalities issues are described in section 4.16 of the final appraisal consultation.

**Approved by Centre or Programme Director (name):** Meindert Boysen

**Date:** 12 April 2011